Replies to post #153527 on Biotech Values

[oc631]

Two weeks ago GILD added Arm-17, and Arm-18 to this ongoing study. So testing of Sofosbuvir/GS-5885 and Sofosbuvir/5885/riba in GT2/GT3 has begun.

Edit: Arm-18 and Arm-19 are GT2/GT3 without riba.

[genisi]

Sofosbuvir/GS-5885 in GT2/GT3 has begun.

Good find! and we were right thinking GILD would try this combo.

[DewDiligence]

Arms 14 and 15 include GS-9669, a non-nuke!

[genisi]

GILD reports SVR4 for sofosbuvir+GS-5885+ribavirin in null responders and more updates:

http://finance.yahoo.com/news/gilead-provides-hepatitis-c-development-133000022.html